M MOVEMENT SOLUTIONS Pain · movement · connection
LANCE LABNO, PT, DPT, LMT · A WRITTEN EXCHANGE WITH AMAN MAHENDRA

From pain relief
to moving again.

A temporary nerve implant is an intriguing starting point. The bigger opportunity is helping people recover safe movement, confidence, and daily life after surgery.

Evidence reviewed November 16, 2026 · Independent Movement Solutions discussion brief · Not a Northwestern study protocol or endorsement

Curiosity, clinical experience,
and a few useful questions.

My perspective on the project, ready for a written exchange.

Subject: Re: Temporary nerve stimulation and orthopedic recovery

Hi Aman,

Thank you for reaching out. I’d be glad to share my perspective. I’m a physical therapist and massage therapist, a Northwestern Feinberg DPT graduate (2006), and the owner of Movement Solutions in Wilmette. I’ve worked in rehabilitation since 1997 and opened Movement Solutions in 2009. My work includes persistent pain, orthopedic and postsurgical recovery, movement coordination, and helping people become more aware of how they move. I draw on manual therapy, movement retraining, graded strengthening, and clinical neurodynamics.

One idea I’d bring to your project is that pain can speak to us for many reasons. Tissue healing and nerve irritation matter, and so can previous experiences, expectations, sleep, stress, and how supported or in control someone feels. Some of these influences operate outside conscious awareness. Pain deserves attention, but its intensity does not give us a direct measurement of tissue damage or tell us the cause by itself.

I’m interested in what this device could make possible: getting out of a chair, walking to the bathroom, sleeping, or participating in appropriate rehabilitation. I also wonder about the meaning the device takes on. It might become associated with relief and confidence; for some people, its sensations or presence could become associated with uncertainty or pain. Actual irritation or a device complication would also need to be investigated. I would want the research to distinguish these possibilities rather than assume one explanation.

I see an important place for technology that supports life and function—stents and shunts are familiar examples when appropriately indicated. Alongside that, my broader interest is helping people understand their bodies, move with more confidence, and connect with other people. Attachment and interpersonal neurobiology offer questions about trust, choice, and support, although they do not yet tell us who will benefit from this implant.

Please send me a list of your team’s questions, along with the specific paper or device description, the surgery you are considering, and its current stage of development. I can work through them thoughtfully by email at my own pace. I’ve gathered the research and possible study questions on this page as a starting point.

Best,
Lance Labno, PT, DPT, LMT
Movement Solutions

Background checked against the Movement Solutions biography. [31] The research behind the questions is explained below.

What changes the signal.
What changes the experience.

Pain often draws attention and prompts protection. It is not a reliable meter of damage, and it does not always carry a decipherable message. Biological, psychological, and social processes can contribute together. [12]

2D / RELATIONSHIP MAP

Follow a connection; then ask what could be observed.

Contributors to pain and movementSix connected domains surround pain and movement: body and nerve, learning, movement, relationships, sleep and stress, and meaningful activity. Lines indicate relationships to investigate, not proven causal effects for this implant.Pain & movementone person · many contributorsBody & nerveHealing · inflammation · device effectsLearning & expectationPrevious care · predicted relief or harmMovement & loadCapacity · coordination · restrictionsRelationships & choiceTrust · responsiveness · autonomySleep & stressRecovery conditions · attentionMeaningful activityParticipation · confidence · daily life

Conceptual synthesis. Lines mean “consider together,” not measured causal strength. This map does not diagnose a person’s pain.

3D / THREE CONNECTED LAYERS

Rotate to see the layers. Flatten to read them together.

01 · BODYTissue, nerves & deviceWhat is happening physically?
02 · EXPERIENCELearning & expectationWhat does this sensation predict?
03 · RELATIONSHIPSChoice, trust & supportWhat helps this person participate?

A conceptual 3D model, not brain anatomy, a biological hierarchy, or measured distances. The layers coexist: physical mechanisms, learned meaning, and relationship context. Color and depth imply no evidence ranking.

Evidence heatmap: where does the support come from?

Read across each row before carrying a finding into this proposed implant study. Colors mark evidence type; words show its reach. This is a scoped evidence map, not a formal GRADE certainty assessment.

Human trialsAnimal testsContext / mixed findingsFrameworkGap
Evidence reviewed November 16, 2026. Select a row’s title to open its source entry.
Claim or approachMechanism / effect studiedClinical recovery relevanceAman’s exact implant
Electrical / thermal Rogers prototypesAnimal tests [1–3]Not established hereExact device unconfirmed
Clinical percutaneous PNSHuman randomized trials [6–7]Some pain/function benefitDifferent hardware
Learned cues & expectationsHuman experiments [24–28]Clinical wording result [27]Implant transfer untested
Attachment & supportMixed human findings [9–11,14]No reliable responder ruleUntested moderator
Right-brain regulation / IPNBConceptual synthesis [13,30]No implant outcome trialUntested framework

A quadrant for better experiments

These are four study conditions, not four kinds of patients. The axes indicate whether an investigational device and an added support/practice program are included. All groups retain appropriate usual care.

Added support + practice ↑
B / SUPPORT

Usual care + structured support

Test explanation, preferred support, and permitted movement practice.

D / COMBINED

Device + structured support

Test the novel relationship: does support help translate analgesia into participation?

A / COMPARATOR

Usual care

Establish the recovery course with ethical, credible control procedures.

C / DEVICE

Usual care + device

Estimate device benefit with the same basic communication and rehabilitation access.

Investigational device added →

Proposed 2×2 factorial design, contingent on device safety, approvals, feasibility, and a power calculation. A sham may be appropriate only if ethically acceptable. Interaction tests require more power than a small feasibility pilot.

Novel hypothesis: the combination could change task participation even when resting pain changes little. Test whether the combined effect differs from the sum of separate effects; do not assume synergy.

Could the treatment itself
become a cue?

A device has physical effects and an experience attached to it. Its appearance, sensations, or treatment setting might come to predict relief, uncertainty, or pain. That is a plausible research question—not an established problem with Rogers’s implant.

Physical pathway

Surgical healing, inflammation, nerve effects, stimulation delivery, or a device complication can contribute to pain.

Investigate symptoms and device function clinically.

Learning and context pathway

Prior experiences, instructions, attention, and expectations can change pain and willingness to move—even with the same experimental stimulus. [24] [25]

Measure meaning and expectations alongside physical findings.
Both pathways can be present. Pain is real in either case. Fluctuation, normal imaging, or improvement with reassurance does not establish a nocebo diagnosis. New or worsening pain around an implant requires assessment for surgical, tissue, nerve, and device-related causes.
Primary experimentWhat happenedWhat it does not establish
Jensen 2012
40 healthy volunteers [24]
After visible cues were paired with high/low heat, masked cues changed pain ratings at test.Supports nonconscious triggering of learned responses. Does not show unconscious initial learning, hidden trauma, or an implant effect.
Bingel 2011
Experimental heat pain [25]
With fixed opioid concentration, positive and negative expectations changed observed analgesia.Does not mean expectations cancel drug pharmacology or explain every treatment failure.
Karacaoglu 2023
Sham TENS [26]
Conditioning/instructions produced nocebo effects with differences across visits and groups.External sham device, not an implant. Fibromyalgia did not produce the hypothesized stronger nocebo response.
Varelmann 2010
140 obstetric patients [27]
Gentler versus harsher anticipatory wording: median immediate injection pain 3 versus 5 out of 10.A short procedure, not long-term recovery. Supports accurate, measured language; never withholding risk information.
Thomaidou 2020
140 enrolled; 122 included [28]
Laboratory counterconditioning reduced learned nocebo pain more than extinction.Clinical transfer remains unproven. This is not a reason to deliberately induce fear or pain after surgery.
Meulders 2011
Movement–pain learning [29]
Movement paired with pain acquired threat value in an experimental setting.Does not make all guarding learned, unnecessary, or safe to override.

Turn the concern into an ethical feasibility study

  1. Before exposure: ask what the person expects to feel, what benefit or harm they anticipate, and which treatment experiences shape those expectations. Record baseline symptoms and function.
  2. During use: align symptom timing with device parameters, activity, sleep, medication, and clinical findings. Worsening pain may prompt device use, so a correlation can run in either direction.
  3. Investigate reported problems: assess physical and device causes before attributing symptoms to expectations. Record tolerability, skin/tissue issues, motor and sensory effects, and adverse events.
  4. Test a support component: compare equally accurate explanations, transparent familiarization, or patient-chosen support. Preserve consent, rescue care, and the ability to stop; no deceptive settings changes in routine care.
  5. Measure participation: record movement pain, permitted task performance, assistance, confidence, and delayed symptoms. Analyze expectation and attachment measures as exploratory moderators—not exclusion labels.

These are proposed research steps requiring clinical investigators, ethics review where applicable, and an appropriate analysis plan. A small pilot can establish feasibility; it cannot validate a responder algorithm.

Body, mind, and connection.

Dan Siegel’s interpersonal neurobiology (IPNB) brings embodied experience, mental processes, and relationships into one interdisciplinary framework. “Integration” refers to linking differentiated elements. It is a way to organize questions—not a proven implant treatment. [30]

Notice

Can the person describe what they feel and distinguish location, intensity, timing, and the task involved?

Observe: symptom descriptions and task-specific responses.

Choose

Does the person understand the plan and have meaningful control over permitted options?

Observe: understanding, perceived agency, and preferences.

Connect

Does support feel responsive and welcome? Who, if anyone, does the person want involved?

Observe: trust, preferred support, and participation.

These are proposed operational questions inspired by IPNB. Neither IPNB nor right-brain attachment theory establishes which neural process is causing an individual’s pain. Attachment involves distributed systems; “right brain” is not a readiness score. [13] [23]

Technology can support a necessary function.

ExamplePhysical roleQuestion for whole-person care
Coronary stent [32]Helps hold a narrowed artery open when clinically indicated.What ongoing care, understanding, and activity support does the person need?
CSF shunt [33]Diverts cerebrospinal fluid for selected hydrocephalus cases.Can the person recognize problems and follow the monitoring plan?
Proposed temporary nerve implantIntended nerve modulation or block; exact mechanism still needs confirmation.Does relief translate into safe activity, and what experience does the person have while using it?

These examples illustrate different purposes, not equivalent evidence or indications. Body awareness and social support do not replace a clinically necessary device.

Lance’s clinical emphasis: helping people understand their bodies, explore appropriate movement, and connect with others can sit alongside effective technology. The research should test how those pieces work together.

What is their study about?

Aman’s email describes an entrepreneurship team exploring a possible use for technology—not a confirmed clinical trial.

What we know from the email

Aman identifies himself as a Northwestern industrial engineering senior, Class of 2027, with a computer science minor and Kellogg certificate. His team wants clinician interviews about early orthopedic recovery and a temporary nerve stimulation implant associated with Professor John Rogers.

The exact device, course instructor, teammates, protocol, sponsor, and clinical development stage are not supplied.

The useful question to bring

“Can the device create a useful window for safe movement—and what else does a person need to use that window?”

This is a proposed clinical framing for Lance to review. It is not a quote from Aman or a claim that the implant already improves rehabilitation.

Continue in writing: Aman can send his questions and the exact device paper. Lance can respond thoughtfully by email, at his own pace.

How the idea could help—and what could be missing

Potential valueMissing piece to testMovement Solutions contribution
Localized, adjustable analgesiaDoes benefit occur during walking, transfers, or exercise—not only at rest?Choose repeatable, surgery-appropriate tasks.
Less reliance on rescue medicationComparable pain control, side effects, sleep, and actual medication useConnect analgesia timing with therapy participation.
A temporary interfaceWorking lifetime, breakdown products, retained components, and failure/removal planTest whether the whole setup is practical at home.
More opportunity to practice movementStrength, sensation, balance, surgical restrictions, and delayed symptom responseDocument both what a person can do and the support needed.
A stronger recovery experienceWhether explanation, choice, and preferred support add benefitHelp design a reproducible communication approach.

These are proposed benefits and design questions. Existing clinical PNS trials support investigating analgesia; they do not validate every Rogers prototype. [6] [7]

“Temporary nerve implant” can mean different things.

The closest wording match is the 2022 electronic pain-block cuff. That is a research lead, not identification of Aman’s device. Ask for the paper, patent, or technical brief.

Animal evidence

Electrical nerve block · 2022

Lee and colleagues developed a bioresorbable cuff delivering kilohertz-frequency alternating current to block conduction in rat peripheral nerves. Reported fast, reversible block; experimental power/control used external connections.

Must establish: human benefit, onset responses, selective sensory effects, and safe motor function. This is not interchangeable with low-frequency clinical PNS. [1]

Animal evidence

Cooling cuff · 2022

Reeder and colleagues used a soft, bioresorbable microfluidic interface to cool a nerve and reversibly reduce conduction. It requires fluid delivery; it is not an electrical stimulation implant.

Must establish: temperature safety, selective effects, home hardware burden, and human recovery outcomes. [2]

Animal evidence

Heating interface · 2026 volume

Park and colleagues report a largely bioresorbable cuff with a heater and temperature sensor. Rat sciatic conduction was suppressed and recovered on cooling; wireless power was demonstrated. First online December 2025.

Must establish: human thermal safety and what remains after degradation. Gold elements are biocompatible, not bioresorbable. [3]

Open two related platforms that address different goals +

2025 wireless dual stimulator: Ahn and colleagues studied peripheral nerve regeneration in animal models. Regeneration is a different endpoint from early postoperative analgesia. [4]

2026 programmable polyphasic system: Kim and colleagues developed wireless power and light-controlled waveforms. The reported platform includes cardiac and diaphragm applications; its existence does not establish pain relief after orthopedic surgery. [5]

Keep three distinctions visible: stimulation ≠ conduction block; temporary ≠ fully dissolving; animal nerve response ≠ better human recovery. No supplied source identifies Aman’s exact device or establishes its regulatory status.

A research network, with roles to confirm.

Only Aman and John Rogers are named in the email. Publication authors below are relevant to the technology; their involvement in Aman’s course team has not been confirmed.

Person / connectionVerified relevanceUseful question
Aman Mahendra
Student contact
Education and project purpose are self-described in the email. The linked professional profile lists Northwestern education, 2023–2027. [17]Which course, instructor, teammates, and specific device are involved?
John A. Rogers
Northwestern professor
Director of the Querrey Simpson Institute for Bioelectronics; expertise in soft, bio-integrated and transient electronics. Coauthor of the candidate devices. [18]Which mechanism and development milestone are relevant now?
Matthew R. MacEwan
WashU collaborator
Research spans peripheral nerve interfaces, regeneration, and transient electronics. Coauthor on electronic and thermal pain-block work. [1] [3] [19]How are nerve health, motor effects, and repeat-use safety evaluated?
Geumbee Lee / Emily Ray
2022 publication authors
Lead authors on the electronic pain-block paper; Lee is also a corresponding author of the thermal interface paper. [1] [3]What does the prototype actually block, for how long, and with what external equipment?
Jeonghwan Park / Hak-Young Ahn
Recent device authors
Park leads the thermal-interface paper; Ahn leads the wireless dual-stimulator paper and coauthors the thermal work. [3] [4]Which performance measures transfer to a postsurgical use case?
Colin K. Franz
Shirley Ryan AbilityLab
Physician-scientist and Electrodiagnostic Laboratory director studying neural injury, repair, and transient bioelectronic implants. Corresponding author on the 2025 regeneration study. [4] [21]Could a rehabilitation collaborator help distinguish nerve recovery, analgesia, and functional performance?
Brian Ilfeld / Johnathan Goree
Independent clinical comparators
Lead authors of clinical PNS trials discussed below. Not established as members of Aman’s or Rogers’s project. [6] [7]What can an acute or persistent-pain trial teach about controls and endpoints?

No faculty member is assumed to teach Aman’s entrepreneurship course. Credentials support expertise, not the effectiveness of a particular device.

Promising human evidence. Different hardware.

Randomized pilot · 66 patients

Acute orthopedic recovery: Ilfeld et al., 2021

Fourteen days of percutaneous PNS or sham followed ambulatory orthopedic surgery. In the first week, median opioid use was 5 versus 48 mg oral morphine equivalents; mean daily average pain was 1.1 versus 3.1 out of 10. Both groups also received a single-injection nerve block. [6]

Active PNS1.1 / 10
Sham3.1 / 10

Bars use a 0–10 pain scale. Group means, not an individual prediction. Pilot size, mixed surgeries, and a different device limit transfer to Rogers’s prototypes.

Randomized trial · persistent pain

After knee replacement: Goree et al., 2024

During weeks 5–8, at least 50% pain reduction occurred in 12/20 PNS participants (60%) versus 5/21 sham participants (24%). Six-minute walking distance also improved more with PNS at end of treatment. This studied persistent pain after knee replacement—not the first postoperative week. [7]

Small study; devices remained for eight weeks. DoD and SPR Therapeutics supported the study. Review disclosures and the full protocol before choosing it as a model.

Randomized trial · 317 patients

Why a credible control matters: Rakel et al., 2014

TENS during knee-replacement rehabilitation reduced some movement pain compared with standard care, but did not significantly outperform placebo TENS. Anxiety and catastrophizing were associated with some response differences. TENS is a surface treatment, not the proposed implant. [8]

Do not turn these exploratory associations into implant eligibility rules. Measure expectations and assess whether participants can guess their allocation.

Laboratory experiment · 39 women

Partner presence was not universally soothing

Krahé et al. found higher attachment avoidance was associated with greater laser-pain ratings when a partner was present rather than absent. This was a particular laboratory context, not surgical recovery. [9]

Laboratory experiment · 37 women

Support helped one sensory outcome; attachment did not moderate it

Jaltare et al. found a smaller area of experimentally induced secondary hyperalgesia during partner handholding. Attachment did not moderate that support effect. Different support, setting, and outcome can yield different findings. [10]

Observational clinical cohort

Attachment findings changed with clinical context

Pfeifer et al. compared unexplained musculoskeletal pain rehabilitation with hip-replacement care for osteoarthritis. Greater avoidance related to less pain improvement in the former and greater improvement in the latter. Different populations and treatments prevent a causal interpretation. [11]

What this means: investigate benefit with good controls. Do not combine these unlike studies into a single success percentage, or use attachment style to predict who will respond to this implant.

The person receiving the signal matters too.

Pain is a real sensory and emotional experience shaped by biological, psychological, and social influences. Nociceptive activity alone does not tell us everything about a person’s pain. [12]

What “right-brain attachment” adds

Allan Schore’s regulation theory emphasizes early attachment, nonverbal communication, emotional regulation, and right-hemisphere contributions. It offers a conceptual reason to attend to voice, timing, facial expression, and interpersonal comfort. [13]

Boundary: this is a theoretical synthesis, not evidence that a right-brain intervention improves implant outcomes. Attachment and pain cannot be reduced to a single hemisphere. A small social-emotion imaging study found task-dependent associations in both right- and left-sided regions. [23] No reviewed study establishes a “right-brain readiness” test for this device.

Turn the theory into observable choices

Ask whether the person wants a preview, quiet practice, verbal coaching, a support person, or more control over pauses. Explain what sensations to expect and what should prompt stopping.

Record perceived safety, confidence for a specific task, participation, and adverse responses. Do not infer attachment from eye contact, muscle guarding, pain intensity, HRV, or a clinician’s impression.

This is a proposed care-and-study approach. It does not measure hemispheric activity or prove a neural mechanism.

Use dimensions and preferences, not fixed boxes.

Possible tendencyQuestion worth askingSupport to offer and test
Worry that help will disappear“What would make the plan feel more predictable?”Consistent explanations, a clear check-in plan, and a stop signal.
Preference for self-reliance or distance“Would you prefer to try independently, with me nearby?”Choice, privacy, and optional coaching; do not force closeness.
Mixed or changing preferences“What is helpful right now?”Recheck preferences across tasks and days.

These are conversation prompts, not diagnostic categories. With consent, the ECR-RS questionnaire could measure attachment anxiety and avoidance as separate dimensions. Specify whether the target is close relationships generally or one particular relationship. It is an exploratory research measure, not an implant-response screen. [22] In using it, select its version, permissions, and scoring with a qualified behavioral researcher. People with insecure attachment may still improve substantially.

Open the evidence gaps and mixed findings +

A 72-person chronic-pain rehabilitation study reported comparable treatment effectiveness across attachment groups. [14] A sequential-block clinician-training study found mixed results and did not establish a clear main pain benefit over usual care. It was not a randomized implant trial. [15]

A post-cesarean attachment pilot is indexed, but the accessible PubMed record has no abstract. Its results are not used here; obtain the complete paper before drawing conclusions. [16]

No reviewed evidence demonstrates that attachment-informed communication changes the electrical effect of this implant, identifies a validated responder subgroup, or prevents persistent postsurgical pain.

Test the device, the recovery, and the support.

Proposed research sequence—not an approved protocol. Start with the smallest study that resolves the current uncertainty.

A

Understand the problem

Interview patients, therapists, surgeons, and anesthesia staff about one procedure and the first two weeks. Ask for concrete episodes: getting to the bathroom, rising from a chair, or sleeping.

Output: a task map, current treatment pathway, and practical barriers. Interviews test need and feasibility, not efficacy. Use consent and de-identified examples.

B

Establish readiness

Review exact-device bench and animal data, functional lifetime, tissue response, motor/sensory effects, degradation, and recovery after shutoff.

Gate: qualified investigators determine readiness, regulatory requirements, and ethics approval before any investigational implantation. Do not translate animal settings into clinical doses.

C

Run a clinical feasibility pilot

Once authorized, choose one surgery and standardized usual care. Test placement, home operation, retention, follow-up, safety, and whether the chosen task can be measured reliably.

Output: recruitment and missing-data estimates, adverse events, and outcome variability to plan a powered trial. A small pilot cannot reliably identify responder subgroups.

D

Test incremental benefit

Compare active device + usual care with credible sham + the same usual care, if an invasive sham is ethically justified. Keep rescue analgesia available. Use concealed allocation and blinded outcome assessment.

Alternative: an active-comparator trial when sham is unsuitable, acknowledging expectancy and masking limitations.

Two studies that do not require the implant

Prospective recovery cohort: follow one surgical population using the measurement schedule below. This can identify recovery predictors and practical barriers, but cannot tell whether a characteristic predicts extra benefit from the device.

Support feasibility experiment: with appropriate research review and consent, compare a structured, patient-chosen preview-and-coaching approach with an equally attentive standard explanation. Maintain usual analgesia and therapy in both groups. Measure acceptability, task completion, pain, and confidence; partner involvement or touch is optional. This can test the support component while device development continues.

Then ask whether communication adds benefit.

A later, adequately powered 2 × 2 factorial trial could separate device effects from an added structured support intervention. Everyone receives respectful care, rehabilitation, and rescue treatment.

Proposed four-arm design—no participant data
Usual supportive communicationAdded structured support
Active deviceDevice benefit under usual careDevice + added choice, preview, and check-ins
Control deviceReference conditionAdded support without active stimulation

Match contact time where possible. Define the support script and fidelity checks; do not train staff to diagnose attachment by behavior. Predefine the interaction analysis. A benefit from support would not, by itself, prove Schore’s proposed mechanism.

A practical measurement schedule

WhenMeasureWhy
Before surgeryBaseline pain and function; medications; sleep; expectations; anxiety; optional attachment dimensions and support preferencesDescribe participants and prespecify a few plausible modifiers.
Early recovery / days 1–14Pain during the same safe task; distance or time; assistance needed; strength/sensation; rescue medication; adverse eventsSeparate analgesia from useful, safe activity.
Weeks 2 and 6Patient-specific function; treatment burden; participation; medication use; device/tissue reviewLook beyond a single immediate pain score.
Months 3 and 6Persistent pain, function, nerve symptoms, further treatmentAssess durability and delayed harms; do not assume prevention.

Illustrative measurement choices. Timing, loading, and permitted movement must match the operation and surgeon’s restrictions. No patient data is collected.

How to identify who benefits more

Predicting recovery is different from predicting treatment benefit. A person might improve with either treatment. A useful responder model must estimate whether the device adds benefit compared with control.

  1. Prespecify a small set of candidate modifiers: procedure, baseline function, pain phenotype, medication exposure, and selected psychosocial measures.
  2. Analyze treatment-by-characteristic interactions, preferably using continuous scores rather than arbitrary “high/low” categories.
  3. Adjust for baseline status and surgical site; plan missing-data handling and multiple comparisons before recruitment. Have a statistician power the primary outcome and any confirmatory interactions.
  4. Validate a proposed selection rule in new patients and sites before using it clinically. Report uncertainty, calibration, harms, and who was underrepresented.
  5. Use attachment information to improve access and support—not to deny treatment or blame a person for pain.
A meaningful win: less task-related pain plus clinically meaningful function, without unacceptable weakness, sensory loss, falls, or device burden. Predefine the primary endpoint and procedure-specific meaningful difference with patients and clinicians; do not invent a universal success cutoff.

A useful direction for the next exchange.

Aman can send his team’s questions in writing. These five questions help identify what would make the project useful and testable.

1. Which exact device and clinical problem are you studying?+

Please send the paper or technical description, intended surgery, mechanism, external equipment, and development stage.

Recommendation: Start with one clearly defined surgery and prototype; distinguish entrepreneurship discovery from a clinical protocol.

2. What should a person be able to do better?+

Choose a meaningful task and describe the expected improvement in pain, assistance, capacity, or participation.

Recommendation: Pair a pain measure with one safe, repeatable functional task and adverse-event monitoring.

3. Could the device become a cue for relief or threat?+

How will you capture expectations and the experience of using it while investigating physical causes of symptoms?

Recommendation: Include a small expectations-and-experience component; avoid labeling people as nocebo-prone.

4. What support belongs beside the device?+

Could explanation, choice, permitted movement practice, or patient-preferred human support improve the recovery experience?

Recommendation: Pilot a reproducible support component, then consider the four-condition design shown above.

5. How will you learn who benefits without prematurely excluding people?+

Which baseline measures and treatment interactions would you prespecify, and how would you validate any responder claim?

Recommendation: Use continuous measures, adequate sample size, uncertainty intervals, and independent validation. Attachment is exploratory, not an eligibility rule.

Sources & reading notes

This is a targeted research synthesis, not a systematic review. Searches covered primary device papers, university profiles, human pain trials, attachment experiments, and clinical cohorts. Strongest direct evidence and conflicting findings are included. Sources were reviewed through accessible full text or abstracts; access limitations are marked.

  1. Lee et al. (2022). A bioresorbable peripheral nerve stimulator for electronic pain block. Science Advances. ↗

    Primary animal/device study; Rogers-group full-text copy available.

  2. Reeder et al. (2022). Soft, bioresorbable coolers for reversible conduction block of peripheral nerves. Science. ↗

    Primary animal/device study. Cooling mechanism.

  3. Park et al. (2026; online 2025). A Bioresorbable Neural Interface for On-Demand Thermal Pain Block. ↗

    Primary animal/device study; full text reviewed. Most, not all, components bioresorbable.

  4. Ahn et al. (2025). Bioresorbable, wireless dual stimulator for peripheral nerve regeneration. ↗

    Primary animal study; regeneration endpoint.

  5. Kim et al. (2026). A wirelessly powered, light-controlled, bioresorbable stimulation system with programmable polyphasic waveforms. ↗

    Primary platform study; not a human orthopedic analgesia trial.

  6. Ilfeld et al. (2021). Percutaneous Peripheral Nerve Stimulation for Postoperative Pain: A Randomized, Sham-Controlled Pilot Study. ↗

    66 patients; 14-day PNS; early postoperative outcomes.

  7. Goree et al. (2024). Randomized Placebo-Controlled Trial of 60-Day PNS After Knee Replacement. ↗

    Persistent pain population; small randomized trial; financial support disclosed in publisher record.

  8. Rakel et al. (2014). TENS for pain during rehabilitation after total knee arthroplasty. ↗

    317 participants; randomized, blinded, placebo-controlled trial.

  9. Krahé et al. (2015). Attachment style moderates partner presence effects on pain: a laser-evoked potentials study. ↗

    39 women; laboratory pain and partner presence; limited generalizability.

  10. Jaltare et al. (2023). The impact of the social context on the development of secondary hyperalgesia. ↗

    37 women; partner handholding experiment; abstract reviewed.

  11. Pfeifer et al. (2018). Impact of attachment behavior on the treatment process of chronic pain patients. ↗

    Observational cohorts; musculoskeletal pain rehabilitation and hip replacement.

  12. International Association for the Study of Pain (2020). Revised definition of pain and notes. ↗

    Authoritative terminology; distinguishes pain from nociception.

  13. Schore (2022). Right brain-to-right brain psychotherapy: recent scientific and clinical advances. ↗

    Author’s theoretical review. Does not test orthopedic implants.

  14. Andersen (2012). Does attachment insecurity affect the outcomes of a multidisciplinary pain management program? ↗

    72-person cohort; attachment did not determine rehabilitation effectiveness.

  15. Attachment-informed clinician training study (2019), Journal of Clinical Medicine 8(3):364. ↗

    Sequential-block design, not randomized; mixed findings and exploratory mediation.

  16. Querney et al. (2024). Adult attachment style as a predictor for post-cesarean pain: a pilot study. ↗

    Indexed letter; no abstract in accessible record. Results not used.

  17. Aman Mahendra: supplied professional profile. ↗

    Public education listing; project details come from supplied email. Do not confuse activity by other people with Aman’s biography.

  18. Northwestern: John Rogers, Institute for Bioelectronics. ↗

    Official faculty profile and research expertise.

  19. Washington University: Neural Engineering research faculty. ↗

    Official research listing for MacEwan; publication affiliation is used for the specific studies.

  20. Rogers Research Group: 2026 journal publications. ↗

    Official publication list; used to check newer related platforms.

  21. Shirley Ryan AbilityLab: Colin Franz, MD, PhD. ↗

    Official clinical and research profile.

  22. Fraley laboratory: Experiences in Close Relationships–Relationship Structures questionnaire. ↗

    Measure developer guidance; separate anxiety/avoidance dimensions and relationship targets.

  23. Vrtička et al. (2012). Attachment and social emotion processing: functional imaging study. ↗

    Small healthy-adult study; task-dependent, distributed regional findings, not a surgical treatment study.

  24. Jensen et al. (2012). Nonconscious activation of placebo and nocebo pain responses. ↗

    Two laboratory experiments, 40 healthy volunteers; visible acquisition followed by visible or masked cue testing.

  25. Bingel et al. (2011). The effect of treatment expectation on drug efficacy. ↗

    Fixed-concentration remifentanil and experimental heat pain; not an implant trial.

  26. Karacaoglu et al. (2023). Nocebo hyperalgesia with sham TENS in fibromyalgia and healthy controls. ↗

    69 at baseline, 56 at follow-up. Mixed group/time findings; no evidence of greater nocebo effects in fibromyalgia.

  27. Varelmann et al. (2010). Nocebo-induced hyperalgesia during local anesthetic injection. ↗

    Randomized wording experiment, 140 obstetric patients; immediate injection pain.

  28. Thomaidou et al. (2020). Learning mechanisms in nocebo hyperalgesia. ↗

    140 enrolled; 122 included. Laboratory conditioning and attenuation; clinical transfer unproven.

  29. Meulders et al. (2011). The acquisition of fear of movement-related pain and associative learning. ↗

    Human experimental movement–pain conditioning; not a postoperative treatment trial.

  30. Dan Siegel. Interpersonal Neurobiology. ↗

    Originator’s explanation of an interdisciplinary framework; not independent confirmation of clinical efficacy.

  31. Movement Solutions. About Lance Labno. ↗

    Official practice biography: massage training 1997, Northwestern DPT 2006, practice founded 2009.

  32. National Heart, Lung, and Blood Institute. Stents. ↗

    Purpose and indications of stents; authoritative patient information.

  33. MedlinePlus. Hydrocephalus. ↗

    Clinical overview including cerebrospinal-fluid diversion with a shunt.